Egetis Therapeutics
5.37 SEK
+0.19 %
Less than 1K followers
EGTX
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Valuation
Income statement
Quarter data
Income statement
Financial statements, revenue, EBIT, valuation metrics, and quarterly estimates for Egetis Therapeutics
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | 82.6 | 40.7 | 22.6 | 22.6 | 57.6 | 46.1 | 62.4 |
| growth-% | -50.7 % | -44.4 % | 0.0 % | 154.9 % | -20.0 % | 35.4 % | |
| EBITDA | -66.5 | -178.0 | -58.8 | -195.4 | -321.2 | -302.4 | - |
| EBIT | -66.7 | -178.4 | -61.3 | -198.1 | -324.8 | -329.4 | -339.9 |
| Profit before taxes | -61.4 | -179.1 | -60.0 | -193.8 | -326.8 | -343.2 | -342.1 |
| Net income | -61.4 | -179.1 | -128.0 | -193.8 | -326.9 | -343.6 | -342.5 |
| EPS | -1.08 | -2.44 | -0.71 | -1.00 | -1.30 | -1.10 | -0.90 |
| Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Dividend ratio | -0.0 % | -0.0 % | -0.0 % | -0.0 % | -0.0 % | -0.0 % | -0.0 % |
Profitability and return on capital
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| EBITDA-% | -80.5 % | -437.8 % | -260.3 % | -864.6 % | -557.6 % | -656.0 % | |
| EBIT-% | -80.8 % | -438.7 % | -271.1 % | -876.5 % | -563.9 % | -714.5 % | -544.7 % |
| ROE | -25.1 % | -28.4 % | -24.3 % | -38.3 % | -59.9 % | -69.7 % | -101.1 % |
| ROI | -22.7 % | -20.0 % | -22.5 % | -34.5 % | -43.0 % | -43.4 % | -53.6 % |